Report cover image

Global Parasitic Diseases Therapeutic Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20557043

Description

Summary

According to APO Research, the global Parasitic Diseases Therapeutic market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Parasitic Diseases Therapeutic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Parasitic Diseases Therapeutic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Parasitic Diseases Therapeutic market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Parasitic Diseases Therapeutic is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Parasitic Diseases Therapeutic market include Pfizer, GlaxoSmithKline, Bayer, Sanaria and F. Hoffmann-La Roche, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Parasitic Diseases Therapeutic, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Parasitic Diseases Therapeutic, also provides the value of main regions and countries. Of the upcoming market potential for Parasitic Diseases Therapeutic, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Parasitic Diseases Therapeutic revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Parasitic Diseases Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Parasitic Diseases Therapeutic company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Parasitic Diseases Therapeutic Segment by Company

Pfizer
GlaxoSmithKline
Bayer
Sanaria
F. Hoffmann-La Roche
Parasitic Diseases Therapeutic Segment by Type

Acaricide
Insect Repellent
Peptides Medicine
Other
Parasitic Diseases Therapeutic Segment by Application

Commercial
Household
Parasitic Diseases Therapeutic Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Parasitic Diseases Therapeutic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Parasitic Diseases Therapeutic key companies, revenue, market share, and recent developments.
3. To split the Parasitic Diseases Therapeutic breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Parasitic Diseases Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Parasitic Diseases Therapeutic significant trends, drivers, influence factors in global and regions.
6. To analyze Parasitic Diseases Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Parasitic Diseases Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Parasitic Diseases Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Parasitic Diseases Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Parasitic Diseases Therapeutic industry.
Chapter 3: Detailed analysis of Parasitic Diseases Therapeutic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Parasitic Diseases Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Parasitic Diseases Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Parasitic Diseases Therapeutic Market Size, 2020 VS 2024 VS 2031
1.3 Global Parasitic Diseases Therapeutic Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Parasitic Diseases Therapeutic Market Dynamics
2.1 Parasitic Diseases Therapeutic Industry Trends
2.2 Parasitic Diseases Therapeutic Industry Drivers
2.3 Parasitic Diseases Therapeutic Industry Opportunities and Challenges
2.4 Parasitic Diseases Therapeutic Industry Restraints
3 Parasitic Diseases Therapeutic Market by Company
3.1 Global Parasitic Diseases Therapeutic Company Revenue Ranking in 2024
3.2 Global Parasitic Diseases Therapeutic Revenue by Company (2020-2025)
3.3 Global Parasitic Diseases Therapeutic Company Ranking (2023-2025)
3.4 Global Parasitic Diseases Therapeutic Company Manufacturing Base and Headquarters
3.5 Global Parasitic Diseases Therapeutic Company Product Type and Application
3.6 Global Parasitic Diseases Therapeutic Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Parasitic Diseases Therapeutic Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Parasitic Diseases Therapeutic Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Parasitic Diseases Therapeutic Market by Type
4.1 Parasitic Diseases Therapeutic Type Introduction
4.1.1 Acaricide
4.1.2 Insect Repellent
4.1.3 Peptides Medicine
4.1.4 Other
4.2 Global Parasitic Diseases Therapeutic Sales Value by Type
4.2.1 Global Parasitic Diseases Therapeutic Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Parasitic Diseases Therapeutic Sales Value by Type (2020-2031)
4.2.3 Global Parasitic Diseases Therapeutic Sales Value Share by Type (2020-2031)
5 Parasitic Diseases Therapeutic Market by Application
5.1 Parasitic Diseases Therapeutic Application Introduction
5.1.1 Commercial
5.1.2 Household
5.2 Global Parasitic Diseases Therapeutic Sales Value by Application
5.2.1 Global Parasitic Diseases Therapeutic Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Parasitic Diseases Therapeutic Sales Value by Application (2020-2031)
5.2.3 Global Parasitic Diseases Therapeutic Sales Value Share by Application (2020-2031)
6 Parasitic Diseases Therapeutic Regional Value Analysis
6.1 Global Parasitic Diseases Therapeutic Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Parasitic Diseases Therapeutic Sales Value by Region (2020-2031)
6.2.1 Global Parasitic Diseases Therapeutic Sales Value by Region: 2020-2025
6.2.2 Global Parasitic Diseases Therapeutic Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Parasitic Diseases Therapeutic Sales Value (2020-2031)
6.3.2 North America Parasitic Diseases Therapeutic Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Parasitic Diseases Therapeutic Sales Value (2020-2031)
6.4.2 Europe Parasitic Diseases Therapeutic Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Parasitic Diseases Therapeutic Sales Value (2020-2031)
6.5.2 Asia-Pacific Parasitic Diseases Therapeutic Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Parasitic Diseases Therapeutic Sales Value (2020-2031)
6.6.2 South America Parasitic Diseases Therapeutic Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Parasitic Diseases Therapeutic Sales Value (2020-2031)
6.7.2 Middle East & Africa Parasitic Diseases Therapeutic Sales Value Share by Country, 2024 VS 2031
7 Parasitic Diseases Therapeutic Country-level Value Analysis
7.1 Global Parasitic Diseases Therapeutic Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Parasitic Diseases Therapeutic Sales Value by Country (2020-2031)
7.2.1 Global Parasitic Diseases Therapeutic Sales Value by Country (2020-2025)
7.2.2 Global Parasitic Diseases Therapeutic Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.3.2 USA Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.4.2 Canada Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.6.2 Germany Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.7.2 France Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.7.3 France Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.9.2 Italy Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.10.2 Spain Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.11.2 Russia Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.14.2 China Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.14.3 China Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.15.2 Japan Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.17.2 India Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.17.3 India Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.18.2 Australia Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.22.2 Chile Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.24.2 Peru Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.26.2 Israel Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.27.2 UAE Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.29.2 Iran Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Parasitic Diseases Therapeutic Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Parasitic Diseases Therapeutic Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Parasitic Diseases Therapeutic Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Pfizer
8.1.1 Pfizer Comapny Information
8.1.2 Pfizer Business Overview
8.1.3 Pfizer Parasitic Diseases Therapeutic Revenue and Gross Margin (2020-2025)
8.1.4 Pfizer Parasitic Diseases Therapeutic Product Portfolio
8.1.5 Pfizer Recent Developments
8.2 GlaxoSmithKline
8.2.1 GlaxoSmithKline Comapny Information
8.2.2 GlaxoSmithKline Business Overview
8.2.3 GlaxoSmithKline Parasitic Diseases Therapeutic Revenue and Gross Margin (2020-2025)
8.2.4 GlaxoSmithKline Parasitic Diseases Therapeutic Product Portfolio
8.2.5 GlaxoSmithKline Recent Developments
8.3 Bayer
8.3.1 Bayer Comapny Information
8.3.2 Bayer Business Overview
8.3.3 Bayer Parasitic Diseases Therapeutic Revenue and Gross Margin (2020-2025)
8.3.4 Bayer Parasitic Diseases Therapeutic Product Portfolio
8.3.5 Bayer Recent Developments
8.4 Sanaria
8.4.1 Sanaria Comapny Information
8.4.2 Sanaria Business Overview
8.4.3 Sanaria Parasitic Diseases Therapeutic Revenue and Gross Margin (2020-2025)
8.4.4 Sanaria Parasitic Diseases Therapeutic Product Portfolio
8.4.5 Sanaria Recent Developments
8.5 F. Hoffmann-La Roche
8.5.1 F. Hoffmann-La Roche Comapny Information
8.5.2 F. Hoffmann-La Roche Business Overview
8.5.3 F. Hoffmann-La Roche Parasitic Diseases Therapeutic Revenue and Gross Margin (2020-2025)
8.5.4 F. Hoffmann-La Roche Parasitic Diseases Therapeutic Product Portfolio
8.5.5 F. Hoffmann-La Roche Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.